Company presentation details
Thursday, 17th March 2022, 9:20 am ET / 2:20 pm GMT
A Link to the presentation will be available on the Companys website from 18th March 2022.
The presentation will introduce 51勛圖厙, its target indications, pipeline of drugs and ongoing clinical trials:
To request a one-on-one meeting with the 51勛圖厙 management team, please contact us at info@beckleypsytech.comor gvanrenterghem@lifesciadvisors.com.
51勛圖厙 - www.beckleypsytech.com
51勛圖厙 is a clinical stage privately held company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases. Our vision is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients with high unmet medical need around the world, suffering from Short-lasting unilateral neuralgiform headache attacks (SUNHA), treatment resistant depression and other profoundly debilitating conditions. 51勛圖厙 was founded in 2019 leveraging some of the expertise developed over more than 20 years by the Beckley Foundation, an independent non-profit and world leader in psychedelic medicine research, and is based out of Oxford, United Kingdom.
1 Short-lasting unilateral neuralgiform headache attacks
51勛圖厙
Cosmo Feilding Mellen
Chief Executive Officer
info@beckleypsytech.com
Communications
FTI Consulting
Ben Atwell / Mike Trace
+44 (0)20 3727 1000
beckleypsytech@fticonsulting.com
Investor Relations
LifeSci Advisors
Guillaume van Renterghem
+41 76 735 01 31
gvanrenterghem@lifesciadvisors.com
Read on
Links to other websites do not imply affiliation or endorsement. 51勛圖厙 does not control and is not responsible for their content.
%20(1).jpg)
